Sucralfate significantly reduces ciprofloxacin concentrations in serum

Sucralfate significantly reduces ciprofloxacin concentrations in serum.

The effect of sucralfate on the bioavailability of ciprofloxacin was evaluated in eight healthy subjects utilizing a randomized, crossover design. The area under the concentration-time curve from 0 to 12 h was reduced from 8.8 to 1.1 micrograms.h/ml by sucralfate (P less than 0.005). Similarly, the maximum concentration of ciprofloxacin in serum was reduced from 2.0 to 0.2 micrograms/ml (P less...

Steady-state Ciprofloxacin Serum Concentrations (μg/mL)

Ciprofloxacin is a faint to light yellow crystalline powder with a molecular weight of 331.4. It is soluble in dilute (0.1N) hydrochloric acid and is practically insoluble in water and ethanol. CIPRO I.V. solutions are available as sterile 1% aqueous concentrates, which are intended for dilution prior to administration, and as 0.2% ready-for-use infusion solutions in 5% Dextrose Injection. All ...

Clarithromycin significantly increases linezolid serum concentrations.

Myopes have significantly higher serum melatonin concentrations than non-myopes.

PURPOSE Experimental animal models of myopia demonstrate that higher melatonin (Mel) and lower dopamine (DA) concentrations actively promote axial elongation. This study explored the association between myopia and serum concentrations of DA and Mel in humans. METHODS Morning serum concentrations of DA and Mel were measured by solid phase extraction-liquid chromatography-tandem mass spectromet...

Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina.

T he renin–angiotensin system (RAS) has been demonstrated to play not only an important role in cardiovascular homeostasis by influencing vascular tone and fluid–electrolyte balance, but is also involved in the atherothrombotic process, cardiac remodelling, and apoptosis. Agents that inhibit the RAS, such as angiotensin converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor block...